13D Filing: Baker Bros. Advisors and Aquinox Pharmaceuticals Inc (NASDAQ:AQXP)

Page 5 of 8 – SEC Filing

CUSIP No.    03842B101 Page   5   of  8   Pages

 

1.

NAMES OF REPORTING PERSONS

Felix J. Baker

2.

CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) p

(b)
p

3.

SEC USE ONLY

4.

SOURCE OF FUNDS (See Instructions)

OO

5.

CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
o

6.

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH

7.

SOLE VOTING POWER: 10,936,414

8.

SHARED VOTING POWER: 0

9.

SOLE DISPOSITIVE POWER: 10,936,414

10.

SHARED DISPOSITIVE POWER: 0

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
10,936,414

12.

CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
p

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

46.7%(1)

14.

TYPE OF REPORTING PERSON (See Instructions)

IN, HC

(1) Based on 23,423,150 shares of common stock outstanding as of March 9, 2017, as reported in the Issuer’s Form 10-K filed
with the SEC on March 9, 2017.

Follow Neurogene Inc. (NASDAQ:NGNE)